AJANTPHARM3,540.00

Ajanta Pharmaceuticals Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersALKEMIPCALABTORNTPHARMABBOTINDIAANTHEMGLAXOMEDANTAGLENMARKMcap ₹44,374 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations4,208.74,648.15,452.95,776.2
Other Income84.694.5172.1216.6
Total Income4,293.34,742.65,624.95,992.8
Expenses
+ Cost of Materials Consumed939.4846.6916.51,005.9
+ Purchases of Stock-in-Trade166.4249.8229.8245.1
+ Changes in Inventories-39.2-25.637.5-15.3
+ Employee Benefit Expense900.31,089.71,291.21,369.4
+ Finance Costs7.220.716.114.0
+ Depreciation & Amortisation135.4144.1173.1176.4
+ Other Expenses1,069.91,228.21,583.11,704.0
Total Expenses3,179.43,553.44,247.34,499.5
EBITDA1,171.91,259.51,394.81,467.1
EBIT1,036.51,115.41,221.71,290.7
Profit
PBT before Exceptional Items1,113.91,189.21,377.71,493.3
Pretax Income1,113.91,189.21,377.71,493.3
+ Current Tax322.1312.3300.1329.3
+ Deferred Tax-24.3-43.521.629.1
Tax Expense297.8268.8321.7358.4
Net Income816.2920.41,056.01,134.9
+ Net Income — Continuing Ops816.2920.41,056.01,134.9
+ Other Comprehensive Income0.81.929.124.7
Total Comprehensive Income817.0922.21,085.11,159.5
Net Income to Common817.0920.41,056.01,130.6
Per Share
Basic EPS64.8273.5684.5390.84
Diluted EPS64.7773.5384.5190.79
Other Comprehensive Income — detail
+ Other Comprehensive Income1.929.124.7
+ Items NOT to be Reclassified to P&L-3.9-9.0-0.5-0.6
+ Tax on Items NOT to be Reclassified-1.4-3.1-0.2-0.2
+ Tax on Items NOT to be Reclassified — alt tag-1.4
+ Items to be Reclassified to P&L3.37.729.425.0
Comprehensive Income — Owners of Parent0.8922.21,085.11,159.5
Per Share — as-filed variants
Basic EPS — Continuing Operations64.8273.5684.5390.84
Diluted EPS — Continuing Operations64.7773.5384.5190.79
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit3,142.13,577.34,269.14,540.4
Gross Margin %74.6676.9678.2978.61
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)1,113.91,189.21,377.71,493.3
Net Income Adj (tax-effected)816.2920.41,056.01,134.9
EPS Adj64.8273.5684.5390.84
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital25.325.125.125.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.